Učitavanje...
MON-LB085 Blurred Vision and Hypocalcemia after Denosumab Injection in a Patient with Tertiary Hyperparathyroidism
Background: Denosumab is a human monoclonal antibody that targets the receptor activator of nuclear factor kappa B ligand (RANKL). It inhibits osteoclast-mediated bone resorption by binding to receptor. Denosumab prevents skeletal-related events (SREs) from osteoporosis and bone metastasis. However,...
Spremljeno u:
| Izdano u: | J Endocr Soc |
|---|---|
| Glavni autori: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Endocrine Society
2019
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6550768/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-MON-LB085 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|